Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice

Clin Infect Dis. 2023 Nov 30;77(11):e57-e68. doi: 10.1093/cid/ciad500.

Abstract

Staphylococcus aureus bacteremia (SAB) carries a high risk for excess morbidity and mortality. Despite its prevalence, significant practice variation continues to permeate clinical management of this syndrome. Since the publication of the 2011 Infectious Diseases Society of America (IDSA) guidelines on management of methicillin-resistant Staphylococcus aureus infections, the field of SAB has evolved with the emergence of newer diagnostic strategies and therapeutic options. In this review, we seek to provide a comprehensive overview of the evaluation and management of SAB, with special focus on areas where the highest level of evidence is lacking to inform best practices.

Keywords: Staphylococcus aureus bacteremia.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / diagnosis
  • Bacteremia* / drug therapy
  • Bacteremia* / epidemiology
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Staphylococcal Infections* / diagnosis
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / epidemiology
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents